Antonelli Alessandro, Rotondi Mario, Fallahi Poupak, Romagnani Paola, Ferrari Silvia Martina, Buonamano Andrea, Ferrannini Ele, Serio Mario
Metabolism Unit, Department of Medicine and National Research Center, Institute of Clinical Physiology, University of Pisa School of Medicine, Via Roma 67, I-56100 Pisa, Italy.
J Clin Endocrinol Metab. 2004 Nov;89(11):5496-9. doi: 10.1210/jc.2004-0977.
CXC chemokine ligand 10 (CXCL10), an interferon-gamma-inducible chemokine associated with Th1-mediated immune responses, has been proposed as a marker of inflammation in autoimmune diseases. We measured serum CXCL10 concentrations in 223 consecutive patients with newly diagnosed autoimmune thyroiditis (AT), 97 euthyroid controls, and 29 patients with nontoxic multinodular goiter and related this parameter to the clinical phenotype. The three groups were similar in gender distribution and age; among the AT patients, 24% had subclinical hypothyroidism. Serum CXCL10 level was significantly higher in AT patients (157 +/- 139 pg/ml) than in controls (79 +/- 38) or patients with multinodular goiter (90 +/- 32; P < 0.0001). Among patients with AT, CXCL10 levels were significantly higher in those with a hypoechoic ultrasonographic pattern and hypothyroidism. In a multiple linear regression model including age, thyroid volume, hypoechogenicity, hypervascularity, TSH, free T(4), and antithyroid peroxidase, only age (standardized coefficient = 0.39; P = 0.0001) and TSH (standardized coefficient = 0.41; P < 0.0002) were significantly related to serum CXCL10 levels. We conclude that circulating CXCL10 is increased in patients with AT and is associated with hypothyroidism. CXCL10 may be regarded as a marker of a more aggressive thyroiditis leading to thyroid destruction.
CXC趋化因子配体10（CXCL10）是一种与Th1介导的免疫反应相关的γ干扰素诱导趋化因子，已被提议作为自身免疫性疾病炎症的标志物。我们测定了223例新诊断的自身免疫性甲状腺炎（AT）患者、97例甲状腺功能正常的对照者以及29例非毒性多结节性甲状腺肿患者的血清CXCL10浓度，并将该参数与临床表型相关联。三组在性别分布和年龄方面相似；在AT患者中，24%患有亚临床甲状腺功能减退。AT患者的血清CXCL10水平（157±139 pg/ml）显著高于对照组（79±38）或多结节性甲状腺肿患者（90±32；P<0.0001）。在AT患者中，超声检查呈低回声模式且伴有甲状腺功能减退的患者CXCL10水平显著更高。在一个包括年龄、甲状腺体积、低回声性、血管增多、促甲状腺激素（TSH）、游离甲状腺素（T4）和抗甲状腺过氧化物酶的多元线性回归模型中，只有年龄（标准化系数=0.39；P=0.0001）和TSH（标准化系数=0.41；P<0.0002）与血清CXCL10水平显著相关。我们得出结论，AT患者循环中的CXCL10升高，且与甲状腺功能减退相关。CXCL10可被视为导致甲状腺破坏的更侵袭性甲状腺炎的标志物。
